LNP Platforms
Lipid nanoparticles (LNPs) act as advanced nanocarriers for nucleic acid delivery. They help protect the active payload from systemic degradation and deliver it to the intended site of action. By avoiding degradation and increasing delivery of their payload to the cytosol, LNPs enable more efficient & more effective nucleic acid therapeutics.
We believe that customized LNPs are critical enablers in advancing nucleic acid-based products to new levels of prophylactic and therapeutic utility. etherna has built expertise and implemented a suite of experimental approaches to customize LNPs for specific therapeutic applications. Additionally, etherna has advanced proprietary ionizable lipid libraries with different properties that we use to develop cLNPs. Our cLNP development capabilities are evidenced by our innovative and proprietary LNP platforms. We tailored those for specific routes of administration allowing better targeted biodistribution with an improved safety profile. Read below about some examples of cLNPs we have developed. With our expertise, suite of experimental tools and proprietary ionizable lipid libraries, we support the development of LNPs customized for a specific payload and application.
Therapeutic area: cancer vaccines
- Allows preferential distribution to the spleen over the liver and other tissues
- Maximizes T cell response and efficacy for systemic therapeutic vaccines
- PreClinical validation with GLP safety and PK studies in NHP
Therapeutic area: immuno-oncology
- Maximized local mRNA expression in tumor
- Reduced off-target expression in liver
- Reduced reactogenicity and inflammation
Therapeutic area: prophylactic vaccines
- Utilize novel ionizable lipids in proprietary constructs to maximize local mRNA expression
- These formulations also show good tolerability and safety, with very low local reactogenicity
Therapeutic area: auto-immune diseases
- Induction of immune tolerance against auto-antigen
Therapeutic area: liver diseases, secreted factors
- High expression in liver after intravenous administration
